Healthtech VCLink’s Post

#Telangana Governor Dr. Tamilisai Soundararajan has underscored the need for taking #healthtech, particularly innovations by #startups that promise to cut down time and cost of the procedures, to rural populace and the economically weak in order to help improve #healthcare access for them. Telangana Governor presented awards to five start-ups at the BioAsia 2024 valedictory function, in #Hyderabad. The five #startups that received the awards included UR Advanced Therapeutics, ZedBlox Logitech, Descign AI, Lamark Biotech and PlebC Innovations Private Limited.

Healthcare diagnostics startup Neuranics raises $700K in seed round: Neuranics, a healthcare diagnostics startup, has raised $700K in its seed round led by Inflection Point Ventures (IPV).  The proceeds will be used for technology development and clinical validation, enabling the company to progress toward commercial production post-CDSCO licensing.  Founded in 2021 by Praveen Kumar and Ashutosh Patra, Neuranics is developing a point-of-care blood analyzer capable of delivering complete blood count (CBC) results in less than 10 minutes using just a finger-prick sample. The device, designed for primary and emergency settings, offers low maintenance and high efficiency, making it a game-changer for the healthcare industry. At the same time, life-saving treatments for critical conditions like sepsis, severe anemia, and thrombocytopenia, especially in dengue patients, can be initiated promptly, ensuring timely and effective care.  The company has a patent granted, received the CDSCO Test License, and Ethical Approval from AIIMS Delhi, and progressing through clinical trials.  So far, Inflection Point Ventures has invested over Rs 790 crore across over 210 startups. #Healthcare #Diagnostics #Startup

Theranautilus, a deep-tech firm developing nanorobotic solutions for healthcare, has raised $1.2 million in its seed round led by pi Ventures. The round also saw participation from Golden Sparrow Ventures and angel investors including Abhishek Goyal, founder and CEO of Tracxn, and Lalit Keshre CEO of Groww. The proceeds will be used to commercialize nanorobotics-based medical devices, initially targeting dental care applications. Srinivas, Theranautilus develops innovative nanorobotic solutions that address critical dental health challenges. This platform is set to transform issues like dental hypersensitivity, which affects over 2 billion people worldwide and represents a $6 billion market. It offers a long-term solution by using precision-manufactured nanorobots to targeted locations within dental tissues to deliver biocompatible materials. Theranautilus, backed by international patents and technology, aims to develop and commercialize precision theranostics-based interventions to manage cancer therapy and other diseases. Founders: Ambarish Ghosh, Debayan Dasgupta, and Peddi Shanmukh Srinivas Follow Rise & Shine for daily funding deals. Stay ahead, stay motivated with www.riseshine.in #deeptech #startup #funding

Acculi Labs Pvt Ltd, a deep-tech life growth solution provider, has raised $1.5 million in a new investment round at a valuation of $25 million led by SABI HOLDING INDIA LIMITED. Co-founded in May 2017 by Rupam Das and HARI PRASATH M, Acculi Labs aims to make home-based care available to the patients. Acculi Labs, a pioneering deep-tech life growth solutions provider, was established in May 2017 by co-founders Rupam Das and Hari Prasath M. The company, based in Bengaluru, focuses on making home-based care accessible to patients. Their flagship product, Lyfas, facilitates easy and frequent early diagnostics and monitoring for asymptomatic patients in the initial stages, enabling them to consult their doctors promptly. Acculi Labs has successfully raised $1.5 million in a recent investment round led by Sabi Holding India Ltd, following a previous seed funding round of Rs 5 crore led by PirE Ventures in 2020. The newly acquired funds will be directed towards advancing the development of conscious AI insights systems, enhancing workforce, operational efficiency, and infrastructure expansion, as stated in a recent press release. Initially, the company offered a cardiac health assessment system, but with the introduction of Lyfas, they have broadened their range of health solutions. The mobile app, which can capture psychophysiological biomarkers non-invasively, delivers a comprehensive health report within just three minutes. #innovation #management #digitalmarketing #technology #creativity #futurism #startups

Neuranics Lab Secures $700K to Revolutionize Point-of-Care Diagnostics! Neuranics Lab, a healthcare diagnostics startup, has raised $700K in a seed funding round led by Inflection Point Ventures (IPV). About Neuranics Lab: Founded in 2021 by Praveen Kumar Bhagat and Ashutosh Patra, Neuranics is transforming healthcare diagnostics with a point-of-care blood analyzer designed to deliver complete blood count (CBC) results in less than 10 minutes using a simple finger-prick sample. Key Highlights: # Quick Results: Enables faster diagnosis in primary care and emergency settings. # Critical Use Cases: Timely detection of life-threatening conditions like: Sepsis. # Severe anemia. # Thrombocytopenia (including cases in dengue patients). # Cost-Effective & Efficient: Low maintenance with high reliability. Fund Utilization: The funding will be used to- # Advance technology development for the blood analyzer. # Conduct clinical validation to ensure accuracy and reliability. # Progress toward commercial production following CDSCO licensing. Key Achievements : # Patent granted for the blood analyzer. # Received CDSCO Test License and Ethical Approval from AIIMS Delhi. # Currently undergoing clinical trials. IPV’s Role : Inflection Point Ventures has been a significant player in supporting innovation, having invested over ₹790 crore in 210+ startups. Words from the Founders: Praveen Kumar Bhagat, Co-founder: “Our mission is to democratize healthcare diagnostics with quick, reliable, and affordable solutions. This funding accelerates our journey toward revolutionizing care in critical and primary settings.” Why It Matters ? Neuranics Lab’ innovation addresses a critical gap in healthcare diagnostics by offering faster and more accessible solutions, enabling timely life-saving interventions in both urban and rural settings. Congratulations to Neuranics Lab! This funding milestone paves the way for Neuranics Lab to disrupt the healthcare diagnostics space. Aspirants Space ( https://lnkd.in/gYkc-Ni8 )celebrates this achievement and is ready to support Neuranics in finding top talent for its next phase of growth. #AspirantsNews #Neuranics #FundingNews #HealthcareInnovation #Diagnostics #SeedFunding

Ahammune Biosciences Pvt. Ltd., a Pune-based biotech startup, raised $5 million in Series A funding led by pi Ventures, with participation from various investors. The company plans to use the funds for Phase II human clinical trials for vitiligo treatment, expanding its patent portfolio, and enhancing R&D efforts for other immune-mediated skin diseases. Founded in 2016, Ahammune specializes in chronic skin conditions and aims to develop affordable, innovative treatments for dermatological issues. AHAMMUNE BIOSCIENCES is a Pune-based biotech startup co-founded in 2016 by Parul Ganju and Krishnamurthy Natarajan. The company focuses on chronic skin conditions and utilizes its proprietary small molecule therapeutics platform to target and enhance skin health. Ahammune Biosciences aims to create innovative solutions to treat and cure skin diseases, particularly dermatological issues such as vitiligo. The company recently secured $5 million in Series A funding, led by pi Ventures, with participation from other investors including Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, Ideaspring Capital, Kotak Alternate Asset Managers Limited , and Legacy Assets LLP. The fresh funds will be utilized for conducting Phase II human clinical trials for drug candidates, expanding the patent portfolio, and advancing Ahammune's research and development (R&D) efforts for other immune-mediated skin diseases. The company's initial program is centered on developing a new drug candidate for vitiligo, which has a unique mechanism of action, capable of stopping patch spread and stimulating the function of color-producing cells in the skin, resulting in repigmentation. Factacy.ai Congratulates and wishes them well. #innovation #management #digitalmarketing #technology #creativity #futurism #startups

📢 CTAN invests over $800k in ICHOR Vascular! Central Texas Angel Network is thrilled to announce its substantial investment of over $800,000 in ICHOR Vascular Inc., a company revolutionizing peripheral clot removal. ICHOR's innovative solution for Peripheral Artery Disease (PAD) and Deep Vein Thrombosis (DVT) eliminates the need for traditional drug therapies and surgeries. Jean Cheever, a key CTAN Deal Team member, said, "ICHOR’s creation of a solution that has the potential to not only enhance patient outcomes but also drive down healthcare costs substantially.” Tim Blair, CEO of ICHOR Vascular, expressed gratitude, "This funding will expedite our efforts to bring our innovative solution to market...we need better tools for patients, and we need to address health economics that plague our health system." Stay tuned for more exciting updates from CTAN as we continue to support groundbreaking ventures! #AngelInvesting #HealthcareInnovation #MedicalTech #StartupFunding #AustinTX #Entrepreneurs #Startups Read the full press release:

The second day - 𝐃𝐞𝐦𝐨 𝐃𝐚𝐲 will feature five dynamic startups competing in a Pitching Competition, where they will present their groundbreaking ideas and solutions to a jury, composed of esteemed investors. 👨💼 We announce NetHub Catalyst startup participants: 𝐓𝐞𝐚𝐦 𝐃𝐨𝐜𝐭 👉 Specialised in a revolutionary telemedicine platform, they are currently focused on insurance, with significant potential for expansion into various areas such as telemedicine, radiology services, and booking software for private clinics and hospitals Team members: Alen Pecirep, Marko Barić, Andrej Tomas 𝐓𝐞𝐚𝐦 𝐀𝐩𝐢𝐨𝐭𝐢𝐱 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 👉 They are dedicated to research and development of innovative products as alternatives to antibiotics, aiming to improve the health of humans, animals, plants, and their shared environment. Their product, Apinol360, is an anti-inflammatory ingredient designed for dermocosmetics Team members: Jelena Šuran, Bozo Radic, MD PhD, Vlado Sliskovic 𝐓𝐞𝐚𝐦 𝐗𝐢𝐩𝐡𝐨𝐢𝐝 👉 Dedicated to developing an innovative medical device - the BoneSense Smart Drill. This smart orthopedic device enables precise bone drilling, virtual orientation, and depth visualization in orthopedic surgery Team members: Arsen Ivanisevic, Zvonimir Boban, Josip Jurić 𝐓𝐞𝐚𝐦 𝐃𝐨𝐤𝐭𝐨 👉 Dokto is developing a web application designed to simplify the search for healthcare services and appointment booking. Their focus is on integrating private and public healthcare providers in the Split-Dalmatia County, improving access to healthcare services and information Team members: Martina Šoljić, Antonija Peshevski, Oliver Mandić 𝐓𝐞𝐚𝐦 𝐖𝐚𝐯𝐞𝐟𝐨𝐫𝐦 👉 The Waveform team has developed an innovative product, SomnoShield—a smart AI-powered wristband designed to predict apnea episodes. It monitors sleep and emits gentle impulses to interrupt apnea episodes without waking the user Team members: Petar Solic, Ivan Pavlinac Dodig Time is running out, spots are filling up! See you in Split on Thursday and Friday. 👋 #HealthTechAdriaConference #HealthTech #HTAdria #Adriatic #Croatia #SplitCroatia #startups #competition

ShiraTronics Secures $66M to Advance Novel Therapy for Migraine MedTech startup ShiraTronics, Inc. has secured $66 million in Series B funding round to advance implantable neuromodulation device for treatment-resistant migraine to FDA-approved pivotal clinical trials, the company announced last Wednesday. Co-founded in 2018 by Mudit K. Jain, PhD, CEO and partner at Treo Ventures, ShiraTronics leverages advanced technologies to develop an effective therapy for chronic migraines. The company’s series B round was led by a new investor Norwest Venture Partners, with notable contributions from Seroba., the Global BioAccess Fund, and OSF HealthCare, alongside other undisclosed strategic investors. The round also saw the participation of existing investors Amzak Health, U.S. Venture Partners, Aperture Venture Partners, and Treo Ventures. Read more: https://lnkd.in/gjxksabM #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #MedicalDevice #MigraineTreatment #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

🚀 Weekly Pulse: Healthcare Startup Funding Roundup 🏥💡 Exciting times in the healthcare startup ecosystem! This week saw a flurry of funding activities and strategic partnerships across various sectors. From dental tech to biotech innovations, here's a snapshot of six promising startups making waves: Roger has secured €7M seed funding led by GV (Google Ventures) and Partech. Their platform streamlines patient communication and admin tasks in dental practices, potentially increasing revenue by 25% and saving 90 minutes daily. OrthoLazer Orthopedic Laser Centers have received $3.5M to expand nationwide. Founded by Dr. Scott Sigman MD, they provide non-opioid pain management using the FDA-cleared MLS M8 Robotic Laser, offering innovative solutions for orthopedic care. Shiftnex.ai has raised $2M for their AI-powered workforce management platform in healthcare. It optimizes staffing based on real-time patient acuity data, aiming to improve care quality and operational efficiency in healthcare facilities. Phosphorex , backed by Ampersand Capital Partners, this CDMO specializing in nanoparticle drug delivery received strategic investment from NOF CORPORATION (nof.co.jp). The funding will enhance cGMP capabilities and advance innovative drug delivery solutions. Endolytix has secured $5M in debt financing to enhance therapies targeting difficult-to-treat bacterial infections. They're developing novel therapeutics to combat multidrug-resistant antibiotic infections in nontuberculous mycobacterial infections and Mycobacterium tuberculosis. Seed Therapeutics has entered a $1.5B collaboration with Eisai Co., Ltd. to develop molecular glue degraders. Additionally, they raised $24M in Series A-3 financing led by Eisai Co., Ltd., boosting their innovative drug discovery efforts. These investments highlight the continued growth in healthcare technology and biotechnology. What are your thoughts on these developments? #HealthTech #BioTech #Funding #Innovation